Abstract 6035
Background
NY-ESO-1 and LAGE-1a are antigens expressed in several tumours, including non-small cell lung cancer (NSCLC). Previous clinical trials using autologous T cells directed against NY-ESO-1/LAGE-1a have shown objective responses between 40% and 60% in synovial sarcoma, metastatic melanoma and multiple myeloma. Pembrolizumab (PEM) is a monoclonal antibody that blocks PD-1/PD-L1 interaction and increases anti-tumour activity in anti-tumour T cells. Here, PEM will be used in combination with NY-ESO-1/LAGE-1a T-cell receptor engineered patient T cells (GSK3377794) to potentially improve clinical benefit in this patient population.
Trial design
This is a phase Ib/IIa, randomised, multi-arm, open-label study (NCT03709706) of GSK3377794 in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 positive adults with NY-ESO-1 and/or LAGE-1a-expressing tumours. Eligible patients with unresectable Stage IIIb/IV NSCLC are either ineligible for standard-of-care chemoradiotherapy, have received PD-1 therapy or appropriate targeted therapy, have terminated prior treatment due to intolerable side effects, or have refused standard approved treatment. At least 30 patients with NSCLC without EGFR or ALK/ROS1 aberrations will be randomised (1:1) to Arm A or B; at least 15 patients with EGFR or ALK/ROS1 aberration will be assigned to Arm C. Patients in Arm A will receive a single IV infusion of GSK3377794; those in Arms B and C will receive GSK3377794 IV on Day 1, then PEM 200 mg starting on Day 22 and continuing for up to 35 cycles or disease progression. Patients in Arm A who progress within 25 weeks post GSK3377794 infusion may receive PEM at the same dose/duration as Arms B and C. The study will have 3 parts: eligibility screening (Part 1); leukapheresis and manufacture of GSK3377794 (Part 2); lymphodepletion and infusion of GSK3377794 (interventional phase; Part 3). Primary objectives are to assess the safety and tolerability of GSK3377794 alone or in combination with PEM and to determine the clinical response. The first patient was screened on December 31, 2018.
Clinical trial identification
NCT03709706.
Editorial acknowledgement
Fiona Woodward, PhD, and Leigh O’Connor-Jones, PhD, of Fishawack Indicia Ltd, UK, funded by GlaxoSmithKline (GSK).
Legal entity responsible for the study
GSK in collaboration with Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
GlaxoSmithKline.
Disclosure
K.L. Reckamp: Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Acea; Research grant / Funding (institution): Adaptimmune; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Exelixis; Honoraria (self), Advisory / Consultancy: Genentech; Research grant / Funding (institution): GSK; Honoraria (self), Advisory / Consultancy: Guardant; Research grant / Funding (institution): Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Loxo Oncology; Research grant / Funding (institution): Molecular Partners; Research grant / Funding (institution): Xcovery; Research grant / Funding (institution): Zeno; Honoraria (self), Advisory / Consultancy: Precision Health; Honoraria (self), Advisory / Consultancy: Seattle Genetics; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self), Advisory / Consultancy: Tesaro. W. Akerley: Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Takeda. E. Calvo: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Project lead: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Nanobiotix; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy: Janssen-Cilag; Honoraria (self), Advisory / Consultancy: GLG; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Non-remunerated activity/ies: PsiOxus Therapeutics; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Honoraria (self), Advisory / Consultancy: Medscape; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): BMS; Honoraria (self), Advisory / Consultancy: Gilead; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Seattle Genetics; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: Cerulean Pharma; Honoraria (self), Advisory / Consultancy: EUSA; Honoraria (self), Advisory / Consultancy: Gehrmann Consulting; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Project lead: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy: Guidepoint; Honoraria (self), Advisory / Consultancy: Servier; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AbbVie; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Amcure; Honoraria (self), Advisory / Consultancy: OncoDNA; Honoraria (self), Advisory / Consultancy: Alkermes; Leadership role, Full / Part-time employment, Director, Clinical Research; employed as medical oncologist: START Madrid; Leadership role, Full / Part-time employment, Director, Clinical Research; employed as medical oncologist: HM Hospitals Group; Leadership role, Co-director: Methods in Clinical Cancer Research (MCCR) ; Leadership role, Founder and president, non-for-profit Foundation: INTHEOS; Shareholder / Stockholder / Stock options: START Madrid; Shareholder / Stockholder / Stock options: Oncoart Associated; Shareholder / Stockholder / Stock options: International Cancer Consultants; Research grant / Funding (institution): ACEO; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Cytomx; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): H3; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Kura; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Loxo; Research grant / Funding (institution): Nektar; Research grant / Funding (institution): MacroGenics; Research grant / Funding (institution): Menarini; Research grant / Funding (institution): Merus; Research grant / Funding (institution): PharmaMar; Research grant / Funding (institution): Principia; Research grant / Funding (institution): PUMA; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Taiho; Research grant / Funding (institution): Tesaro; Research grant / Funding (institution), Project lead: BeiGene; Research grant / Funding (institution): Transgene; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Innovio; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Mersana; Research grant / Funding (institution): Daiichi; Research grant / Funding (institution): ORCA; Research grant / Funding (institution): Boston Therapeutics; Research grant / Funding (institution): Dynavax; Research grant / Funding (institution): DebioPharm; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): Millenium; Research grant / Funding (institution): Synthon; Research grant / Funding (institution): Spectrum; Research grant / Funding (institution): Rigonetec; Non-remunerated activity/ies, Membership: SEOM; Non-remunerated activity/ies, Membership: EORTC; Leadership role, Membership, non-remunerated: ESMO; Leadership role, Membership, non-remunerated: ASCO. J. Clarke: Research grant / Funding (institution), Research Grant Principle Investigator: Medpacto; Advisory / Consultancy, Research grant / Funding (institution), Principle Investigator: Eli Lilly; Research grant / Funding (institution), Principle Investigator: Bristol-Myers Squibb; Research grant / Funding (institution), Principle Investigator: Genentech; Research grant / Funding (institution), Principle Investigator: Spectrum; Research grant / Funding (institution), Principle Investigator: Adaptimmune; Research grant / Funding (institution), Principle Investigator: Bayer; Research grant / Funding (institution), Principle Investigator: AbbVie; Research grant / Funding (institution), Principle Investigator: Moderna; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Guardant; Honoraria (self), Advisory / Consultancy: AstraZeneca. M.J. Edelman: Advisory / Consultancy, Advisor/board member: WindMIL Therapeutics; Advisory / Consultancy, Consultant/Independent Contractor: Armo; Advisory / Consultancy, Consultant/Independent Contractor: BerGen Bio; Advisory / Consultancy, Consultant/Independent Contractor: Syndax; Honoraria (self): AstraZeneca; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Takeda; Shareholder / Stockholder / Stock options: Biomarker Strategies. K. He: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Advisory Board: BMS; Advisory / Consultancy, Consultant: Consultant/Independent Contractor; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Geneplus; Research grant / Funding (institution): Novartis; Research grant / Funding (institution), Travel / Accommodation / Expenses: Mirati; Research grant / Funding (institution), Travel / Accommodation / Expenses: GSK; Research grant / Funding (institution), Travel / Accommodation / Expenses: Adaptimmune. J.W. Neal: Advisory / Consultancy, Research grant / Funding (institution): ARIAD/Takeda; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Exelixis; Advisory / Consultancy, Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy: Jounce Therapeutics; Advisory / Consultancy: Lilly; Advisory / Consultancy: Loxo Oncology; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Nektar; Research grant / Funding (institution): Novartis. S.P. Patel: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Illumina; Advisory / Consultancy: Novartis; Advisory / Consultancy: Tempus; Research grant / Funding (institution): AstraZeneca/MedImmune; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Fate Therapeutics; Research grant / Funding (institution): Genocea; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Iovance; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche/Genentech; Research grant / Funding (institution): Xcovery. J.W. Riess: Advisory / Consultancy, Consultant: Celgene; Advisory / Consultancy, Advisor / board member: Heron; Advisory / Consultancy, Advisor / board member: Loxo; Advisory / Consultancy, Advisor / board member: Boehringer Ingelheim; Research grant / Funding (institution): Spectrum; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Merck. A.G. Sacher: Advisory / Consultancy, Advisory Board Member: Bayer; Honoraria (self): Bayer; Honoraria (self): AstraZeneca; Honoraria (self): Genentech-Roche; Honoraria (self): Merck. S. Turcotte: Advisory / Consultancy: TVM Life Sciences Management Inc.; Research grant / Funding (self): Bristol-Myers Squibb; Honoraria (self): Celgene; Honoraria (self): AstraZeneca; Honoraria (self): Exactis Innovation. L.C. Villaruz: Advisory / Consultancy, Research grant / Funding (institution), Advisor/board member: Pfizer; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Exelixis; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Iovance; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Merck. M.G. Zauderer: Officer / Board of Directors, Non-remunerated activity/ies: Mesothelioma Applied Research Foundation; Advisory / Consultancy, Independent contractor: Aldeyra; Advisory / Consultancy, Research grant / Funding (institution), Independent contractor: Epizyme; Full / Part-time employment, Employee of MSK which receives royalties from IBM (collaboration on Watson for Oncology tool): MSK; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Polaris; Research grant / Funding (institution): Sellas Life Sciences; Research grant / Funding (institution): Millenium; Research grant / Funding (institution): Curis. B. Farsaci: Shareholder / Stockholder / Stock options, Full / Part-time employment: GSK. N. Skoura: Shareholder / Stockholder / Stock options, Full / Part-time employment: GSK. M. Chisamore: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme, Corp., a subsidiary Merck & Co., Inc., Kenilworth, NJ, USA. M.L. Johnson: Honoraria (institution), Advisory / Consultancy: Araxes Pharma; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): BeiGene; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (institution), Advisory / Consultancy: Calithera; Honoraria (institution), Advisory / Consultancy: Genentech/Roche; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Guardant Health; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Incyte; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Loxo Oncology; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Honoraria (institution), Advisory / Consultancy: Mersana Therapeutics; Honoraria (institution), Advisory / Consultancy: Mirati; Honoraria (institution), Advisory / Consultancy: Ribon Therapeutics; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Astellas; Honoraria (institution), Advisory / Consultancy: Otsuka Pharmaceuticals; Research grant / Funding (institution), Travel / Accommodation / Expenses: AbbVie; Research grant / Funding (institution), Travel / Accommodation / Expenses: Clovis; Research grant / Funding (institution), Travel / Accommodation / Expenses: Daiichi Sankyo; Travel / Accommodation / Expenses: Exelixis; Travel / Accommodation / Expenses: Sysmex Inostics; Travel / Accommodation / Expenses: Vapotherm; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Acerta; Research grant / Funding (institution): Adaptimmune; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Apexigen; Research grant / Funding (institution): Array BioPharma; Research grant / Funding (institution): Birdie; Research grant / Funding (institution): Checkpoint Therapeutics; Research grant / Funding (institution): Clovis; Research grant / Funding (institution): Corvus; Research grant / Funding (institution): Cytomx; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Dynavax; Research grant / Funding (institution): G1 Therapeutics; Research grant / Funding (institution): Genocea; Research grant / Funding (institution): Gritstone; Research grant / Funding (institution): Hengrui Therapeutics, Inc.; Research grant / Funding (institution): Kadmon; Research grant / Funding (institution): Lycera; Research grant / Funding (institution): Neovia; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): OncoMed; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): Syndax; Research grant / Funding (institution): Tarveda. All other authors have declared no conflicts of interest.
Resources from the same session
681 - Significance of the red blood cell distribution width in resected pathological stage I non-small cell lung cancer
Presenter: Gouji Toyokawa
Session: Poster Display session 1
Resources:
Abstract
3336 - Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)
Presenter: Rolf A. Stahel
Session: Poster Display session 1
Resources:
Abstract
2204 - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Presenter: María Guirado
Session: Poster Display session 1
Resources:
Abstract
1446 - A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis
Presenter: Bo Cheng
Session: Poster Display session 1
Resources:
Abstract
1788 - Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)
Presenter: Cristina Alfaro Autor
Session: Poster Display session 1
Resources:
Abstract
2299 - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer
Presenter: Abdurrahman Işıkdoğan
Session: Poster Display session 1
Resources:
Abstract
4211 - Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors
Presenter: Xueru Zhu
Session: Poster Display session 1
Resources:
Abstract
1550 - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)
Presenter: Vicente Palomar Abril
Session: Poster Display session 1
Resources:
Abstract
2345 - Meta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC
Presenter: Bernardo Rapoport
Session: Poster Display session 1
Resources:
Abstract
3747 - Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
Presenter: Yu Miura
Session: Poster Display session 1
Resources:
Abstract